Regeneron Pharmaceuticals
REGN
742.12
+3.40
+0.46%
Regeneron Pharmaceuticals
US · REGN
#285 by market cap
Listed 1970
742.12
+3.40
+0.46%
Live - 5344 symbols - heartbeat 548s ago
· 2026-10-08 05:13
Pre-market
742.00
-0.02%
After-hours
742.12
0.00%
Overnight
741.93
-0.03%
- Market cap
- 76.40B
- P/E (TTM)i
- 18.36
- P/Bi
- 2.41
- EPSi
- 41.48
- Div yieldi
- 0.49%
- 52W posi
- 63%
Reader sentiment
Are you bullish or bearish on REGN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 7.22, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +0.99% YoY
Margins
- Gross margin
- 85.35%
- Operating margin
- 25.81%
- Net margin
- 31.41%
Key ratios & quality
- PEG ratioi
- 14.54
- Altman Z-Scorei
- 7.22
PEG uses trailing P/E against the 3-year net income growth rate (1.26%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.15B | 6.56B | 8.50B | 16.07B | 12.17B | 13.12B | 14.20B | 14.34B |
| Gross profit | 4.73B | 5.79B | 7.38B | 13.63B | 10.61B | 11.30B | 12.23B | 12.24B |
| Selling & admin expenses | 1.13B | 1.34B | 1.35B | 1.82B | 2.12B | 2.63B | 2.95B | 2.70B |
| Research & development | 1.47B | 2.45B | 2.74B | 2.86B | 3.59B | 4.44B | 5.13B | 5.85B |
| Operating profit | 2.53B | 2.21B | 3.58B | 8.99B | 4.99B | 4.23B | 4.09B | 3.70B |
| Pretax profit | 2.55B | 2.43B | 3.81B | 9.33B | 4.86B | 4.20B | 4.78B | 5.23B |
| Tax | 109.10M | 313.30M | 297.20M | 1.25B | 520.40M | 245.70M | 367.30M | 725.80M |
| Net profit | 2.44B | 2.12B | 3.51B | 8.08B | 4.34B | 3.95B | 4.41B | 4.50B |
| Basic EPS | 23 | 19 | 33 | 76 | 41 | 37 | 41 | 43 |
| Diluted EPS | 21.29 | 18.46 | 30.52 | 71.97 | 38.22 | 34.77 | 38.34 | 41.48 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 3.03B | 3.68B | 3.75B | 3.88B | 3.61B | 4.29B |
| Gross profit | 2.56B | 3.15B | 3.23B | 3.30B | 2.94B | 3.71B |
| Selling & admin expenses | 633.00M | 634.20M | 657.80M | 775.00M | 647.70M | 662.10M |
| Research & development | 1.33B | 1.42B | 1.48B | 1.63B | 1.54B | 1.63B |
| Operating profit | 604.00M | 1.09B | 1.11B | 898.60M | 744.80M | 1.42B |
| Pretax profit | 905.00M | 1.52B | 1.76B | 1.04B | 831.20M | 1.53B |
| Tax | 96.30M | 127.10M | 303.30M | 199.10M | 104.00M | 230.90M |
| Net profit | 808.70M | 1.39B | 1.46B | 844.60M | 727.20M | 1.30B |
| Basic EPS | 8 | 13 | 14 | 8 | 7 | 13 |
| Diluted EPS | 7.27 | 12.81 | 13.62 | 7.86 | 6.75 | 12.23 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 6.45B | 7.69B | 9.78B | 14.01B | 15.88B | 19.48B | 18.66B | 18.02B |
| Cash & ST investments | 2.81B | 3.21B | 3.59B | 5.69B | 7.74B | 10.84B | 9.01B | 8.61B |
| Inventory | 1.15B | 1.42B | 1.92B | 1.95B | 2.40B | 2.58B | 3.09B | 3.20B |
| Total assets | 11.73B | 14.81B | 17.16B | 25.43B | 29.21B | 33.08B | 37.76B | 40.56B |
| Total current liabilities | 1.44B | 2.10B | 2.70B | 3.93B | 3.14B | 3.42B | 3.94B | 4.37B |
| Short-term debt | -- | -- | -- | 719.70M | -- | -- | -- | -- |
| Long-term debt | -- | -- | 1.98B | 1.98B | 1.98B | 1.98B | 1.98B | 1.99B |
| Total liabilities | 2,977,200,000.00 | 3,715,500,000.00 | 6,138,000,000.00 | 6,666,000,000.00 | 6,550,500,000.00 | 7,107,100,000.00 | 8,405,800,000.00 | 9,301,800,000.00 |
| Total equity | 8.76B | 11.09B | 11.03B | 18.77B | 22.66B | 25.97B | 29.35B | 31.26B |
| Retained earnings | 5.25B | 7.38B | 10.89B | 18.97B | 23.31B | 27.26B | 31.67B | 35.80B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 17.57B | 16.86B | 17.98B | 18.02B | 18.21B | 18.45B |
| Cash & ST investments | 8.35B | 7.47B | 8.44B | 8.61B | 8.75B | 7.99B |
| Inventory | 3.19B | 3.21B | 3.25B | 3.20B | 3.10B | 3.08B |
| Total assets | 37.55B | 38.22B | 40.17B | 40.56B | 40.87B | 41.73B |
| Total current liabilities | 3.57B | 3.67B | 4.43B | 4.37B | 5.11B | 5.53B |
| Short-term debt | -- | -- | -- | -- | 720.00M | 720.00M |
| Long-term debt | 1.98B | 1.99B | 1.99B | 1.99B | 1.99B | 1.99B |
| Total liabilities | 8,157,600,000.00 | 8,280,300,000.00 | 9,211,600,000.00 | 9,301,800,000.00 | 9,445,200,000.00 | 10,019,200,000.00 |
| Total equity | 29.39B | 29.94B | 30.96B | 31.26B | 31.42B | 31.71B |
| Retained earnings | 32.38B | 33.68B | 35.05B | 35.80B | 36.42B | 37.62B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2.20B | 2.43B | 2.62B | 7.08B | 5.01B | 4.59B | 4.42B | 4.98B |
| Depreciation & amortization | 148.20M | 210.30M | 235.90M | 286.20M | 341.40M | 421.00M | 482.90M | 543.70M |
| Free cash flow | 1.81B | 2.00B | 2.00B | 6.53B | 3.40B | 3.67B | 3.54B | 3.77B |
| Dividends paid | -- | -- | -- | -- | -- | 0 | 0 | -370.30M |
| Stock buybacks / issuance | -77.10M | -252.10M | -3.95B | -1.01B | -1.01B | -1.79B | -2.17B | -3.33B |
| Ending cash balance | 1.48B | 1.63B | 2.21B | 2.90B | 3.12B | 2.74B | 2.49B | 3.12B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 1.05B | 1.14B | 1.62B | 1.17B | 1.08B | 813.00M |
| Depreciation & amortization | 126.90M | 135.10M | 136.70M | 145.00M | 123.20M | 123.70M |
| Free cash flow | 773.60M | 737.60M | 1.37B | 880.00M | 799.40M | 521.80M |
| Dividends paid | -93.80M | -92.60M | -91.20M | -92.70M | -97.80M | -96.80M |
| Stock buybacks / issuance | -985.10M | -1.04B | -626.70M | -687.40M | -704.40M | -1.13B |
| Ending cash balance | 3.09B | 2.02B | 2.51B | 3.12B | 2.97B | 2.47B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 32.81 | 21.32 | 31.77 | 54.21 | 20.94 | 16.26 | 15.95 | 14.87 |
| ROA %i | 23.85 | 15.94 | 21.98 | 37.91 | 15.88 | 12.69 | 12.46 | 11.50 |
| ROIC %i | 30.30 | 20.14 | 27.94 | 45.25 | 18.43 | 13.16 | 12.54 | 11.89 |
| 5-year avg ROE %i | 22.61 | 23.87 | 26.13 | 32.55 | 32.21 | 28.90 | 27.83 | 24.44 |
| EBIT margin %i | 38.47 | 31.28 | 45.51 | 58.38 | 40.40 | 32.57 | 34.05 | 36.77 |
| FCF / sales %i | 27.00 | 25.44 | 23.58 | 40.63 | 27.91 | 27.96 | 24.92 | 26.25 |
| Current ratioi | 4.47 | 3.67 | 3.63 | 3.56 | 5.06 | 5.69 | 4.73 | 4.13 |
| Quick ratioi | 3.50 | 2.86 | 2.86 | 2.98 | 4.16 | 4.82 | 3.86 | 3.28 |
| Debt / assetsi | 6.04 | 4.82 | 15.71 | 10.61 | 9.25 | 8.17 | 7.16 | 6.67 |
| LT debt / equityi | 8.09 | 6.44 | 24.45 | 10.55 | 11.92 | 10.41 | 9.21 | 8.66 |
| Interest coveragei | 91.55 | 81.43 | 67.97 | 163.75 | 82.80 | 58.52 | 87.59 | 120.42 |
| Revenue CAGR (3Y) %i | 7.83 | 10.50 | 13.11 | 46.18 | 22.90 | 15.57 | -4.04 | 5.62 |
| Net income CAGR (3Y) %i | 56.64 | 33.19 | 43.12 | 48.93 | 27.04 | 4.02 | -18.25 | 1.26 |
| FCF CAGR (3Y) %i | 40.53 | 27.11 | 24.65 | 53.31 | 19.32 | 22.33 | -18.47 | 3.48 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 15.96 | 15.34 | 15.19 | 14.87 | 14.55 | 14.04 |
| ROA %i | 12.51 | 12.00 | 11.80 | 11.50 | 11.28 | 10.83 |
| ROIC %i | 12.59 | 12.07 | 12.14 | 11.89 | 11.48 | 11.09 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 35.72 | 34.55 | 36.41 | 36.77 | 34.89 | 33.61 |
| FCF / sales %i | 21.03 | 25.02 | 27.24 | 26.25 | 25.41 | 23.01 |
| Current ratioi | 4.93 | 4.60 | 4.06 | 4.13 | 3.57 | 3.34 |
| Quick ratioi | 3.90 | 3.57 | 3.19 | 3.28 | 2.84 | 2.63 |
| Debt / assetsi | 7.20 | 7.08 | 6.74 | 6.67 | 6.62 | 6.49 |
| LT debt / equityi | 9.20 | 9.04 | 8.74 | 8.66 | 6.32 | 6.26 |
| Interest coveragei | 105.27 | 134.19 | 123.21 | 120.42 | 108.44 | 94.25 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Collaboration revenue is the largest reported line at 57.22% of revenue, across 9 reported segments.
- EYLEA HD ® follows at 13.90%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Collaboration revenue57.22%
EYLEA HD ®13.90%
EYLEA ®9.61%
Libtayo ®7.98%
Other revenue4.51%
Libtayo3.42%
Praluent ®1.74%
Evkeeza ®1.24%
Lynozyfic ®0.38%
Quote time 2026-10-08 05:13:24 · For reference only, not investment advice and not tailored to your situation.